The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Tiracoxib     4-(4-cyclohexyl-2-methyl-1,3- oxazol-5-yl)...

Synonyms: Tilmacoxib, tilmacoxibum, JTE-522, CHEMBL34913, SureCN379564, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of JTE-522


Psychiatry related information on JTE-522

  • Starting at 4 weeks of age, the treated group (T group) were given a diet containing JTE-522, a selective COX-2 inhibitor, and the control group (C group) were given a control diet [5].

High impact information on JTE-522


Chemical compound and disease context of JTE-522


Biological context of JTE-522


Anatomical context of JTE-522


Associations of JTE-522 with other chemical compounds


Gene context of JTE-522

  • These data indicate that the COX-2 inhibitor JTE-522 has a high potential for use as a clinical agent for the treatment of liver metastasis of colon cancer [11].
  • JTE-522 downregulated PDGF production by LM-H3 but had no influence on VEGF production [11].
  • JTE-522 also inhibited MMP-2 secretion by LM-H3 [11].
  • Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522 [21].
  • In contrast, the inhibitory activity of JTE-522 on human COX-1 was not affected by preincubation time [19].

Analytical, diagnostic and therapeutic context of JTE-522

  • Furthermore, the adjunct use of JTE-522 is shown to significantly enhance treatment efficacy of conventional anticancer drugs not only in vitro but also in vivo without causing any noticeable side effects [2].
  • We also examined the effects of JTE-522 on the production of growth factors and MMPs through the use of ELISA and gelatin zymography, respectively [11].
  • The diameter of tumor vessels and the size of lung metastases significantly and positively correlated with neovascularization in the control group, but not in the JTE-522-treated groups [3].
  • Effect of JTE-522 on KGF expression from NF-21 cells and OCUM-2M cells was analyzed by ELISA and RT-PCR [15].
  • Oral administration of JTE-522 significantly decreased the size of xenografted tumor coinoculated with OCUM-2M cells and NF-21 cells in nude mice [15].


  1. JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis1. Yamamoto, H., Kondo, M., Nakamori, S., Nagano, H., Wakasa, K., Sugita, Y., Chang-De, J., Kobayashi, S., Damdinsuren, B., Dono, K., Umeshita, K., Sekimoto, M., Sakon, M., Matsuura, N., Monden, M. Gastroenterology (2003) [Pubmed]
  2. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. Hida, T., Kozaki, K., Ito, H., Miyaishi, O., Tatematsu, Y., Suzuki, T., Matsuo, K., Sugiura, T., Ogawa, M., Takahashi, T., Takahashi, T. Clin. Cancer Res. (2002) [Pubmed]
  3. JTE-522, a selective COX-2 inhibitor, interferes with the growth of lung metastases from colorectal cancer in rats due to inhibition of neovascularization: a vascular cast model study. Kobayashi, H., Gonda, T., Uetake, H., Higuchi, T., Enomoto, M., Sugihara, K. Int. J. Cancer (2004) [Pubmed]
  4. JTE-522, a selective cyclooxygenase-2 inhibitor, inhibits induction but not growth and invasion of 1,2-dimethylhydrazine-induced tubular adenocarcinomas of colon in rats. Wei, M., Morimura, K., Wanibuchi, H., Shen, J., Salim, E.I., Moku, M., Hakoi, K., Fukushima, S. Int. J. Cancer (2005) [Pubmed]
  5. The role of cyclooxygenase-2 (COX-2) in two different morphological stages of intestinal polyps in APC(Delta474) knockout mice. Sunayama, K., Konno, H., Nakamura, T., Kashiwabara, H., Shoji, T., Tsuneyoshi, T., Nakamura, S. Carcinogenesis (2002) [Pubmed]
  6. Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. Hayashi, N., Yamamoto, H., Hiraoka, N., Dono, K., Ito, Y., Okami, J., Kondo, M., Nagano, H., Umeshita, K., Sakon, M., Matsuura, N., Nakamori, S., Monden, M. Hepatology (2001) [Pubmed]
  7. Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. Ono, K., Akatsu, T., Murakami, T., Kitamura, R., Yamamoto, M., Shinomiya, N., Rokutanda, M., Sasaki, T., Amizuka, N., Ozawa, H., Nagata, N., Kugai, N. J. Bone Miner. Res. (2002) [Pubmed]
  8. JTE-522 selectively inhibits cyclooxygenase-2-derived prostaglandin production in inflammatory tissues. Wakitani, K., Tazaki, H., Matsushita, M., Iwamura, H. Inflamm. Res. (2000) [Pubmed]
  9. Combination chemotherapy with JTE-522, a novel selective cyclooxygenase-2 inhibitor, and cisplatin against gastric cancer cell lines in vitro and in vivo. Sugiura, T., Saikawa, Y., Kubota, T., Suganuma, K., Otani, Y., Watanabe, M., Kumai, K., Kitajima, M. In Vivo (2003) [Pubmed]
  10. Role of kinin and prostaglandin in cutaneous thermal nociception. Matsuzaki, S., Hayashi, I., Nara, Y., Kamata, K., Yamanaka, M., Okamoto, H., Hoka, S., Majima, M. Int. Immunopharmacol. (2002) [Pubmed]
  11. Inhibitory effect of a selective cyclooxygenase-2 inhibitor on liver metastasis of colon cancer. Nagatsuka, I., Yamada, N., Shimizu, S., Ohira, M., Nishino, H., Seki, S., Hirakawa, K. Int. J. Cancer (2002) [Pubmed]
  12. Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer. Mizutani, Y., Kamoi, K., Ukimura, O., Kawauchi, A., Miki, T. J. Urol. (2002) [Pubmed]
  13. Effects of JTE-522, a specific inhibitor of cyclooxygenase-2, on the recurrence of allergic inflammation in rats. Niki, H., Yamada, M., Yamaki, K., Mue, S., Ohuchi, K. Eur. J. Pharmacol. (1998) [Pubmed]
  14. Pharmacokinetics and safety of JTE-522, a novel selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Ikeda, Y., Umemura, K., Kondo, K., Nakashima, M., Kobayashi, T., Takahashi, M. British journal of clinical pharmacology. (2002) [Pubmed]
  15. Selective cyclooxygenase-2 inhibitor downregulates the paracrine epithelial-mesenchymal interactions of growth in scirrhous gastric carcinoma. Yashiro, M., Nakazawa, K., Tendo, M., Kosaka, K., Shinto, O., Hirakawa, K. Int. J. Cancer (2007) [Pubmed]
  16. JTE-522-induced apoptosis in human gastric adenocarcinoma [correction of adenocarcinoma] cell line AGS cells by caspase activation accompanying cytochrome C release, membrane translocation of Bax and loss of mitochondrial membrane potential. Li, H.L., Chen, D.D., Li, X.H., Zhang, H.W., Lü, J.H., Ren, X.D., Wang, C.C. World J. Gastroenterol. (2002) [Pubmed]
  17. Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522. Mizutani, Y., Nakanishi, H., Li, Y.N., Sato, N., Kawauchi, A., Miki, T. J. Urol. (2004) [Pubmed]
  18. Cyclooxygenase-2 participates in the late phase of airway hyperresponsiveness after ozone exposure in guinea pigs. Nakano, H., Aizawa, H., Matsumoto, K., Fukuyama, S., Inoue, H., Hara, N. Eur. J. Pharmacol. (2000) [Pubmed]
  19. Profile of JTE-522 as a human cyclooxygenase-2 inhibitor. Wakitani, K., Nanayama, T., Masaki, M., Matsushita, M. Jpn. J. Pharmacol. (1998) [Pubmed]
  20. Inhibitory effects of JTE-522, a novel prostaglandin H synthase-2 inhibitor, on adjuvant-induced arthritis and bone changes in rats. Masaki, M., Matsushita, M., Wakitani, K. Inflamm. Res. (1998) [Pubmed]
  21. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Tomozawa, S., Nagawa, H., Tsuno, N., Hatano, K., Osada, T., Kitayama, J., Sunami, E., Nita, M.E., Ishihara, S., Yano, H., Tsuruo, T., Shibata, Y., Muto, T. Br. J. Cancer (1999) [Pubmed]
WikiGenes - Universities